AI Article Synopsis
Article Abstract
Background: Selegiline is used to treat Parkinsonian patients. Other indications of its use have recently been discovered.
Objective: Scouting special and beneficial side effects of selegiline treatment.
Method: Two-year old male Wistar rats were daily treated with 0.25 mg/kg of selegiline s.c. (subcutaneous injection). The rats were sacrificed following a four-weeks' treatment.
Results: Mass of testes, number of sperms, progressive motility of sperms, and their viability definitely increased.
Conclusion: Selegiline can successfully be used to stop/counterbalance certain symptoms of aging.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748828 | PMC |
| http://dx.doi.org/10.2174/1874104501711010138 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Formulation, development and in vivo characterization of selegiline hydrochloride nanostructured lipid nanocarrier loaded microneedle array patch for depression.
Int J Pharm
January 2025
Department of Pharmaceutics, Bharti Vidyapeeth Deemed to be University, Poona College of Pharmacy, Erandwane, Pune 411038, Maharashtra, India. Electronic address:
Depression is a common mental condition causing depressed mood and loss of pleasure. The primary treatment approach for the management of depression consists of the use of selegiline (MAO-B) inhibitor compound. The present work aimed to develop and optimize selegiline-loaded nanostructured lipid carriers for transdermal application, utilizing a 2 full factorial design approach.
View Article and Find Full Text PDFAssessment of the level of apoptosis in differentiated pseudo-neuronal cells derived from neural stem cells under the influence of various inducers.
Am J Stem Cells
December 2024
Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences Khorramabad, Iran.
Development and maintenance of the nervous system are governed by a scheduled cell death mechanism known as apoptosis. Very much how neurons survive and function depends on the degree of death in differentiating pseudo-neuronal cells produced from neural stem cells. Different inducers can affect the degree of death in these cells: hormones, medicines, growth factors, and others.
View Article and Find Full Text PDFFluorinated Coumarin Derivatives as Selective PET Tracer for MAO-B Imaging.
J Med Chem
January 2025
Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.
Monoamine oxidase-B (MAO-B), predominantly exists on the outer mitochondrial membrane of astrocytes, serves as a crucial biomarker for reactive astrocytes during neuroinflammatory responses and various neurodegenerative diseases. In this study, we synthesized a series of fluorinated coumarin derivatives and evaluated their structure-activity relationship and subtype selectivity for MAO-B. Following this, the preclinical bioevaluation containing positron emission tomography (PET) imaging and autoradiography studies led to the identification of the novel PET tracer, [F], which demonstrated high affinity for MAO-B (IC = 0.
View Article and Find Full Text PDFFeasibility of Simon 2-Stage Futility Trials in Early Parkinson Disease: Analysis of the PRECEPT and DATATOP Trial Datasets.
Neurology
January 2025
From the Department of Clinical Neurosciences (M.W.K., J.R.S.), University of Calgary, Alberta; Division of Neurology (L.V.K.), Department of Medicine, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Ontario; Department of Medicine (D.W.), University of British Columbia Southern Medical Program, Kelowna; Division of Neurology (T.A.M., M.G.S.), Department of Medicine, University of Ottawa, The Ottawa Hospital Ottawa, Ontario, Canada; Department of Neurology (J.M.), Rijnstate Hospital, Arnhem; Department of Neurology (E.M.M.S., B.U.), MS Center Amsterdam, Amsterdam University Medical Centers, the Netherlands; Section on Statistical Planning and Analysis (A.S.), Department of Neurology, UT Southwestern Medical Center, Dallas; and Department of Biostatistics (G.R.C.), University of Alabama at Birmingham.
Background And Objectives: Disease-modifying treatments (DMTs) are a major unmet need in Parkinson disease (PD). To date, trials investigating DMT candidates in PD most often used a randomized controlled trial (RCT) design. Unfortunately, RCTs to date have not led to a breakthrough, in part because of the large sample sizes and length of follow-up required.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!